These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22163246)

  • 41. Clinical efficacy and changes in the dosages of concomitantly used psychotropic drugs in memantine therapy in Alzheimer's disease with behavioral and psychological symptoms on dementia.
    Suzuki H; Inoue Y; Nishiyama A; Mikami K; Gen K
    Ther Adv Psychopharmacol; 2013 Jun; 3(3):123-8. PubMed ID: 24167684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variation in Placebo Effect Sizes in Clinical Trials of Oral Interventions for Management of the Behavioral and Psychological Symptoms of Dementia (BPSD): A Systematic Review and Meta-Analysis.
    Hyde AJ; May BH; Xue CC; Zhang AL
    Am J Geriatr Psychiatry; 2017 Sep; 25(9):994-1008. PubMed ID: 28363357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.
    Campbell N; Ayub A; Boustani MA; Fox C; Farlow M; Maidment I; Howards R
    Clin Interv Aging; 2008; 3(4):719-28. PubMed ID: 19281064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug therapy of dementia in elderly patients. A review.
    Olsen CE; Poulsen HD; Lublin HK
    Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
    Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
    Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Donepezil for dementia with Lewy bodies: meta-analysis of multicentre, randomised, double-blind, placebo-controlled phase II, III, and, IV studies.
    Mori E; Ikeda M; Ohdake M
    Psychogeriatrics; 2024 May; 24(3):589-596. PubMed ID: 38439217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
    Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment Options for Dementia with Lewy Bodies: A Network Meta-Analysis of Randomised Control Trials.
    Tahami Monfared AA; Desai M; Hughes R; Lucherini S; Yi Y; Perry R
    Neurol Ther; 2020 Dec; 9(2):521-534. PubMed ID: 32495063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China.
    Liu S; Jin Y; Shi Z; Huo YR; Guan Y; Liu M; Liu S; Ji Y
    Aging Ment Health; 2017 Jun; 21(6):651-657. PubMed ID: 26882509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis.
    Jin B; Liu H
    J Neurol; 2019 Oct; 266(10):2363-2375. PubMed ID: 30666436
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy.
    Atri A; Molinuevo JL; Lemming O; Wirth Y; Pulte I; Wilkinson D
    Alzheimers Res Ther; 2013; 5(1):6. PubMed ID: 23336974
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil.
    Kimura T; Takamatsu J
    Neuropsychiatr Dis Treat; 2013; 9():49-53. PubMed ID: 23293526
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trials.
    Molino I; Colucci L; Fasanaro AM; Traini E; Amenta F
    ScientificWorldJournal; 2013; 2013():925702. PubMed ID: 24288512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological interventions for cognitive decline in people with Down syndrome.
    Livingstone N; Hanratty J; McShane R; Macdonald G
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD011546. PubMed ID: 26513128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Donepezil and memantine for moderate-to-severe Alzheimer's disease.
    Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Hughes A; Jacoby R; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Passmore P; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown R; Banerjee S; Onions C; Griffin M; Adams J; Gray R; Johnson T; Bentham P; Phillips P
    N Engl J Med; 2012 Mar; 366(10):893-903. PubMed ID: 22397651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.